Mobile

A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients...

Update Il y a 4 ans
Reference: EUCTR2010-023621-37

A 26-week treatment, multi-center, randomized, double-blind, double dummy, parallel-group study to assess the efficacy, safety and tolerability of QVA149 compared to fluticasone/salmeterol in patients with moderate to severe chronic obstructive pulmonary disease

Woman and Man

  • | Country :
    • -
  • | organs :
    • -
  • | Specialty :
    • -

Extract

To demonstrate the superiority of QVA149 110/50 µg q.d. as compared to fluticasone/salmeterol (500µg /50µg) b.i.d. in terms of standardized FEV1 AUC0-12h following 26 weeks of treatment in patients with moderate to severe COPD.

Inclusion criteria

  • Chronic Obstructive Pulmonary Disease

Links